{"id":"W2220367249","doi":"10.1200/jco.2007.25.18_suppl.4030","title":"XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC)","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Capecitabine; Oxaliplatin; Medicine; Irinotecan; Bevacizumab; Internal medicine; Colorectal cancer; Population; Oncology; Fluorouracil; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005237228,0.0002899047,0.004486106,0.0001857279,0.00008946294,0.000008599008,0.00009426596,0.0001578024,0.00003272664],"category_scores_gemma":[0.007985661,0.0001619959,0.0006324964,0.000177212,0.0003341377,0.00006008571,0.00004332058,0.0002337151,6.289941e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000476657,"about_ca_system_score_gemma":0.001094996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007646924,"about_ca_topic_score_gemma":0.006039229,"domain_scores_codex":[0.9947482,0.0006145986,0.003501963,0.0003436422,0.0004697944,0.0003218065],"domain_scores_gemma":[0.9720991,0.02405143,0.002287586,0.0001602778,0.0009319974,0.000469559],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9261898,0.01031066,0.005015427,0.00001327897,0.004415189,0.0001226286,0.001053701,0.00001385394,0.00003310869,0.000004128429,0.0003313584,0.05249687],"study_design_scores_gemma":[0.8132035,0.1417651,0.03478398,0.0001257297,0.003271986,0.00000655176,0.0002493025,0.00007548864,0.0001376261,0.00004334899,0.006212039,0.0001253931],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906638,0.0003923154,0.0004064436,0.003382713,0.001283271,0.003261304,0.0004207962,0.000007976166,0.0001813682],"genre_scores_gemma":[0.9935703,0.0006199582,0.004696968,0.0001970209,0.0006090818,0.000121396,0.00003654559,0.00002267706,0.0001260104],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1314544,"threshold_uncertainty_score":0.9560159,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1377486985361567,"score_gpt":0.4849429064891192,"score_spread":0.3471942079529625,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}